Vor Biopharma Inc. is a clinical-stage cell and genome engineering therapy company. The Company is engaged in combining a novel patient engineering approach with targeted therapies to provide solutions for patients suffering from hematological malignancies. Its proprietary platform leverages expertise in hematopoietic stem cell (HSC) biology, genome engineering and targeted therapy development to genetically modify HSCs to remove surface targets expressed by cancer cells. The Company’s lead engineered hematopoietic stem cells (eHSC) product candidate include tremtelectogene empogeditemcel (trem-cel), for the treatment for acute myeloid leukemia (AML) and other blood cancers. It is designed to replace the standard of care in transplant settings for patients suffering from acute myeloid leukemia (AML) and other blood cancers. Its VBP101 is a Phase I/II a multicenter, open-label, first-in-human study of trem-cel in patients with AML.
Código da empresaVOR
Nome da EmpresaVor Biopharma Inc
Data de listagemFeb 05, 2021
CEODr. Jean-Paul Kress, M.D.
Número de funcionários159
Tipo de títulosOrdinary Share
Fim do ano fiscalFeb 05
Endereço100 Cambridgepark Drive
CidadeCAMBRIDGE
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal02140
Telefone16176556580
Sitehttps://www.vorbio.com/
Código da empresaVOR
Data de listagemFeb 05, 2021
CEODr. Jean-Paul Kress, M.D.
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.

Sem dados